Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1β blockade to prevent immunothrombosis in pancreatic organ transplant recipients (ILIPO)
2025-524834-24-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Oct 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in diabetes mellitus type 1 (T1D), Pancreas Allograft Rejection and immunothrombosis, sponsored by CHU de Nantes. Primary endpoint: Safety and graft outcomes at 1 year. Planned start Oct 2026; status: authorised.
02
Drugs
anakinra
03
Conditions
diabetes mellitus type 1 (T1D)Pancreas Allograft Rejectionimmunothrombosis
Beyond the preview
Go deeper on 2025-524834-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524834-24-00.